Merck KGaA (BIT:1MRK)
Italy
· Delayed Price · Currency is EUR | Market Cap | 55.78B |
| Revenue (ttm) | 21.27B |
| Net Income (ttm) | 2.96B |
| Shares Out | n/a |
| EPS (ttm) | 6.80 |
| PE Ratio | 18.87 |
| Forward PE | 15.92 |
| Dividend | 2.20 (1.75%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 102 |
| Average Volume | 135 |
| Open | 127.70 |
| Previous Close | 125.95 |
| Day's Range | 127.70 - 128.50 |
| 52-Week Range | 103.40 - 150.00 |
| Beta | n/a |
| RSI | 57.86 |
| Earnings Date | Mar 5, 2026 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables, devices, instruments, software, and services for research, production, and testing; process solutions consisting of filtration devices, chromatography... [Read more]
Financial Performance
In 2024, Merck KGaA's revenue was 21.16 billion, an increase of 0.78% compared to the previous year's 20.99 billion. Earnings were 2.78 billion, a decrease of -1.66%.
Financial StatementsNews
ClearBridge International Value Strategy adds RHHBY and MKGAF; exits GRRMF, AKESF, and HKMPF
Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson
Sanofi stock skidded Thursday after the pharma giant's board ousted Paul Hudson as CEO, replacing him with Merck KGaA's Belen Garijo.
Sanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor'
Sanofi SA (NASDAQ: SNY) on Wednesday decided not to renew the Director mandate of Paul Hudson . As a result, Paul Hudson's last day as Chief Executive Officer will be on February 17, 2026, after his ...
Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case
The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.
Merck KGaA to draw on Valo's drug discovery AI in potential $3 billion deal
Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused on Parkinson's and related diseases that is potentially worth over $3 billio...
Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson's Disease and Related Disorders
LEXINGTON, Mass.--(BUSINESS WIRE)--Valo Health announces collaboration with Merck KGaA, Darmstadt, Germany to discover and develop novel treatments for Parkinson's and related disorders.
Merck KGaA (MKKGY) Q3 2025 Earnings Call Transcript
Merck KGaA (OTCPK:MKKGY) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Florian Schraeder - Head of Investor Relations Belén Garijo López - Chair of Executive Board & CEO Hel...
Germany's Merck KGaA Posts Higher Earnings on Organic Growth Across Units
Merck KGaA's sales grew 5.2%, driven by demand for pharma-production products, rare diseases treatments and semiconductor materials in its electronics unit.
Merck KGaA's Q3 profit rises, beats market view
Merck KGaA reported on Thursday a slight gain in quarterly operating earnings that beat market expectations, benefiting from legislative changes in South America and the sale of a priority review vouc...
Merck KGaA: An AI-Resistant Pharma Play
Merck KGaA (MKGAF) is deeply undervalued, offering a compelling entry point with strong fundamentals and resilience to AI disruption. MKGAF's diversified segments—life science, healthcare (biologics),...
Trump rolls out his latest deal with a drugmaker. This one stems from his campaign promise to cover all IVF costs.
President Donald Trump on Thursday announced a deal with EMD Serono, a subsidiary of German drugmaker Merck KGaA, that aims to cut the out-of-pocket costs for in vitro fertilization, with the move com...
Trump announces efforts to expand access to IVF drugs
President Donald Trump announced two new efforts to expand availability of in vitro fertilization, the first concrete step from the Trump administration on the expensive, decades-old procedure. It inc...
Trump Announces Deal With Germany's Merck on IVF Costs
President Donald Trump announces a deal with Germany's Merck KGaA to cut the price of some of its fertility medicines in exchange for relief from threatened tariffs. He speaks during a a press confere...
Germany's Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets
The company confirmed its 2025 guidance and is targeting annual organic sales growth in the mid-single-digit percentage range and an expansion in profitability over the medium term.
Germany's Merck tweaks mid-term healthcare unit guidance
German pharmaceuticals and technology company Merck KGaA slightly improved its mid-term guidance for its healthcare business ahead of its capital markets day on Thursday.
Chinese police investigating app fraud case, says German drugmaker Merck KGaA
Police in China are investigating an app fraud case, said German healthcare firm Merck KGaA , amid growing concerns over entities claiming affiliation with major corporations.
Merck and Siemens Deepen Strategic Partnership to Accelerate AI and Data-Driven Drug Discovery and Development
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, and Siemens, a leading technology company, signed a new Memorandum of Understanding (MoU), extending their strateg...
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drug...
Merck KGaA, Darmstadt, Germany, Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Ch...
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
Merck KGaA (MKGAF) Q2 2025 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Belen Garijo Lopez - Chair of Executive Board & CEO Danny Bar-Zohar - Member of the Executive B...
Merck KGaA: The Undervaluation Is Now Close To 13-Year Lows
Merck KGaA is deeply undervalued, trading at a P/E below 12.6x versus its 16-18x historical average, presenting a rare buying opportunity. Despite recent setbacks in its CDMO business and pipeline, Me...
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for...
China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical P...